iX Biopharma Secures S\$6.7 Million in Upsized Placement to Drive Aggressive U.S. Expansion
iX Biopharma Secures S\$6.7 Million in Upsized Placement to Drive Aggressive U.S. Expansion
Key Highlights for Investors
- iX Biopharma Ltd. (SGX: 42C) raises S\$6.7 million via upsized private placement, surpassing the initial S\$5.0 million target by 34%.
- Strong institutional demand from major funds, including Lion Global Investors Limited (a member of OCBC Group) and Ginko-AGT Global Growth Fund.
- OCBC Bank acted as Placement Agent for the transaction.
- 67,000,000 new shares issued at S\$0.10 per share.
- Strategic focus on U.S. market expansion through compounding pharmacies, enabling immediate product commercialisation with minimal additional R&D expenditure.
- Emphasis on longevity and healthspan products, particularly the market-leading SL-NAD+ sublingual product.
- Three-pillar growth strategy: Compounding business, wellness business, and drug development division.
Detailed Analysis of the News
In a significant development likely to attract investor attention, iX Biopharma Ltd., a Singapore-listed specialty pharmaceutical company, has successfully closed an upsized share placement, raising S\$6.7 million—well above its initial S\$5.0 million target. The company placed 67 million new shares at S\$0.10 apiece, reflecting robust demand and strong investor confidence in iX Biopharma’s business model and future growth prospects.
The placement drew institutional participation from two prominent funds: Lion Global Investors Limited (part of the OCBC Group) and Ginko-AGT Global Growth Fund. The involvement of such reputable investors is a significant vote of confidence and may be seen as a validation of the company’s turnaround efforts and future strategy. The placement was facilitated by OCBC Bank, which acted as the Placement Agent.
Eva Tan, Chief Commercial Officer of iX Biopharma, emphasized that this capital raise is a “strong endorsement” of the company’s pivot toward the U.S. market, utilizing a compounding pharmacy model. This approach enables iX Biopharma to commercialize its novel sublingual products in the U.S. immediately, sidestepping the need for further R&D and regulatory delays. This is especially impactful for its SL-NAD+ product, designed to support longevity and healthspan—an area seeing explosive growth in demand and valuation.
This strategic shift will give iX Biopharma direct access to the lucrative U.S. healthcare market—the world’s largest. Management has signaled that the company’s core focus will be on compounding and wellness businesses, with additional support from its ongoing drug development division. These three operational pillars are expected to underpin the next phase of iX Biopharma’s growth.
For shareholders, this announcement is highly relevant and potentially price-sensitive:
- The capital injection strengthens the company’s balance sheet, enabling aggressive expansion and execution of its U.S. strategy.
- Early commercialisation of key products in the U.S. may translate into faster revenue recognition and improved financial performance.
- The endorsement by leading institutional funds may trigger renewed investor interest and positive sentiment around the stock.
- Issuance of 67 million new shares at S\$0.10 may have a dilutive effect, but the raised capital and growth prospects could outweigh this concern if execution is successful.
The company has advised stakeholders to read this media release in conjunction with its recent SGXNET announcements dated 28, 30, and 31 October 2025 for a comprehensive understanding of the placement process and its implications.
Contact Information for Further Inquiries
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult their financial advisor before making any investment decisions. The author and publisher accept no liability for any losses or damages arising from the use of this information.
View IX BiopharmaW260718 Historical chart here
